In a notable example of precision oncology and multidisciplinary cancer care, doctors at Fortis Hospital, Bannerghatta Road, Bengaluru, successfully treated a 45-year-old man diagnosed with advanced lung cancer that had spread to his brain.
The patient first received his diagnosis in 2020 and underwent treatment for more than five years at the hospital. Through a combination of multidisciplinary care and precision-guided targeted therapy, doctors were able to achieve sustained disease control despite the aggressive nature of the illness.
Rare Lung Cancer Subtype Diagnosed in a Young Patient
Lung cancer occurring at a relatively young age is uncommon. Further molecular testing revealed that the patient had ALK-positive lung cancer, a rare subtype found in only 5–7% of lung cancer patients.
This genetic mutation made the case both clinically rare and medically challenging. The treatment was led by Dr. Niti Raizada, Principal Director, Medical Oncology and Hemato-Oncology, Fortis Hospitals, Bengaluru.
Initial Diagnosis Reveals Advanced Metastatic Disease
As per the press release, the patient was initially diagnosed at the age of 39, after experiencing persistent fatigue, back pain, breathlessness, and headaches.
Comprehensive investigations revealed advanced metastatic lung adenocarcinoma, a form of non-small cell lung cancer (NSCLC). By the time of diagnosis, the disease had already spread to multiple organs, including lymph nodes, bones, and the brain.
Such extensive spread is typically associated with poor survival outcomes, particularly when the brain is involved. Historically, survival rates in such cases have been below 30%.
Notably, the patient had no major previous illnesses, no family history of cancer, and minimal comorbidities apart from diabetes, making the aggressive onset at a young age particularly unusual.
Multidisciplinary Team Initiates Comprehensive Treatment
Given the complexity of the case, the patient was managed by a multidisciplinary team of specialists at Fortis Hospital Bannerghatta Road. The team included experts from medical oncology, radiation oncology, neurology, and supportive care.
Initially, doctors treated the patient with a combination of chemotherapy, immunotherapy, and bone-strengthening therapy, which resulted in a significant reduction in tumour burden across the body.
After confirming the ALK-positive genetic mutation, the team introduced long-term oral targeted therapy along with bone protection therapy. This precision-guided approach helped achieve sustained disease control over the following years.
Advanced Targeted Therapy Controls Disease Progression
In 2024, imaging scans suggested possible disease progression in the chest lining and brain. The case was reviewed by a multidisciplinary tumour board for further evaluation.
However, additional investigations, including biopsy and spinal fluid examination, did not reveal active malignancy. Consequently, doctors optimized the treatment plan by introducing next-generation targeted therapy using a lorlatinib-based regimen, along with supportive medications.
Subsequent scans showed disease stabilisation and excellent control through early 2025. The patient was recently admitted for scheduled supportive therapy and was later discharged in stable condition, with advice to continue targeted treatment, metabolic monitoring, and regular follow-ups.
Experts Highlight Role of Precision Oncology
Commenting on the case, Dr. Niti Raizada emphasised the importance of molecular diagnosis and targeted treatment.
“Advanced lung cancer with brain metastases in a young patient is uncommon and historically associated with poor outcomes. Identifying ALK-positive disease was a turning point because it allowed us to use precision-targeted therapy. ALK-positive cancers often respond well to advanced targeted medicines, significantly improving long-term outcomes when treated appropriately,” she said.
She added that sustained disease control beyond five years demonstrates the impact of early molecular diagnosis, multidisciplinary care, and access to next-generation targeted therapies.
Coordinated Care Improves Survival and Quality of Life
Dr. Madhusudan N, Senior Consultant in Radiation Oncology at Fortis Hospital Bannerghatta Road, highlighted the importance of long-term monitoring in such cases.
“Managing ALK-positive lung cancer requires careful surveillance and timely optimization of therapy. Through coordinated care, we were able to control brain lesions effectively and support prolonged survival while maintaining a good quality of life for the patient,” he said.
Patient Expresses Gratitude for Care and Support
Reflecting on his journey, the patient expressed gratitude to the medical team.
“When I was first diagnosed, I was worried about my future and my family. The doctors at Fortis guided me with confidence, care, and hope at every step. Today, being able to live a stable and active life years after diagnosis feels truly reassuring,” he said.
Fortis Highlights Strength of Multidisciplinary Cancer Care
Mr. Gautham CB, Facility Director, Fortis Hospital Bannerghatta Road, said the case reflects the hospital’s commitment to advanced oncology care.
“This case highlights the strength of multidisciplinary cancer care at Fortis Hospital Bannerghatta Road. Successfully managing advanced lung cancer with long-term stability demonstrates our focus on delivering personalized, evidence-based treatment that improves patient outcomes,” he said.